Oxford Nanopore Technologies
Corporate/Government Newsroom
From portable to population scale, nanopore devices offer direct analysis of DNA/RNA in-real time ? Source
Actions
Media Outlet details
| Scope | National, Consumer |
|---|---|
| Language | English |
| Country | United Kingdom |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesOxford Nanopore further strengthens executive leadership team
Appointment of Chief Development and Product Officer (CDPO) Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing], today announces the appointment of David Miller as Chief Development and Product Officer (CDPO), joining on 1st September. The Company also confirms that Conor McKechnie will join as Chief Marketing and Communications Officer (CMCO) on 1st October.
Francis Van Parys outlines our priorities for customers in Oxford Nanopore's next phase of growth
As Oxford Nanopore announces its H1 2026 results, CEO Francis Van Parys has shared a new video message with customers, partners and the wider nanopore community, setting out his priorities for the company's next chapter. Six months into the role, Francis reflects on what he has learned from conversations with customers around the world and how that feedback is shaping Oxford Nanopore's focus for the years ahead.
How could nanopore sequencing in clinical labs combat infectious disease?
In hospitals around the world, against a backdrop of pathogens that evade detection and rising antimicrobial resistance (AMR), clinicians continue to fight infectious diseases. Timely access to reliable data is critical to this: what pathogen is causing this infection? Which treatments is it resistant to? Is this infection spreading from patient to patient? Are our control measures working? Now, researchers are bringing Oxford Nanopore sequencing to this fight.
Why use direct RNA sequencing for transcriptomics?
Multiomic data is not optional for answering complex biological questions — it is essential. To link genotype to phenotype, researchers need comprehensive datasets that cover genetics, transcriptomics, epigenetics, epitranscriptomics, and proteomics. Legacy multiomic workflows remain complex and time consuming, requiring multiple different assays, platforms, and analytical approaches.
Validation of a long-read 16S rRNA-gene sequencing approach for analysis of clinical samples and bacterial identification in a routine clinical laboratory
© 2008 - 2026 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, EPI2ME, GridION, MinION, MinKNOW, PromethION, P2 Solo, and P2 are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries.
Nanopore sequencing identifies parent-of-origin specific age-associated methylation changes at imprinted loci in the human genome
© 2008 - 2026 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, EPI2ME, GridION, MinION, MinKNOW, PromethION, P2 Solo, and P2 are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries.
MinION Essentials: Everything you need to know about the world’s most cost-effective and accessible sequencer
Whether you’re curious about MinION, have a device that you don’t use, or want to maximise your current experiments, this webinar will provide practical guidance, tips and real-world advice. Plus, our experts will answer your MinION queries during the session. PLEASE NOTE: This webinar will be offered in two timezones. Please select your preferred option on the form below.
Advancing microbial genomics at Institut Pasteur with the PromethION 2 Integrated
At Institut Pasteur (Pasteur Institute), the Biomics team supports research into infectious diseases across a broad spectrum of organisms — from bacteria and viruses to fungi and parasites. To keep pace with evolving research needs, the group recently added the PromethION 2 Integrated (P2i) device into their workflows. We spoke to Chloé Baum (Institut Pasteur, France) about why they chose the P2i and how it is reshaping the support the team can provide.
Metagenomics in action
Every research question starts with uncertainty. Is there a pathogen present? Which microbes matter? Where is antimicrobial resistance emerging? Answering these questions can require multiple methods, adding time and complexity. Metagenomic sequencing offers a more comprehensive approach, revealing the diversity of complex microbial communities in a single experiment, with insights available in real time.
Science Unlocked: publication picks from June 2026
In this monthly series, we share a selection of recent publications that use Oxford Nanopore sequencing to unlock novel insights. Spanning gene therapy, cancer, and infectious disease, these studies showcase the advances in scientific research made possible by Oxford Nanopore sequencing. Featured in this edition: 1. Comprehensive profiling of gene therapy vectors 2. Resolving structural variants linked to cancer risk 3. Tackling antibiotic resistance in the NHS with 16S sequencing 4.